Monitoring phase II comparative clinical trials with two endpoints and penalty for adverse events

DOI10.1007/s11009-017-9582-3zbMath1395.62334OpenAlexW2742416657MaRDI QIDQ1657815

Takis Papaioannou, Sotiris Bersimis, Athanasios Sachlas

Publication date: 14 August 2018

Published in: Methodology and Computing in Applied Probability (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1007/s11009-017-9582-3

zbMATH Keywords

decision rulespenalizationadverse eventswaiting time distributionphase II clinical trialsMarkov chain embeddable random variablesbivariate sequences of trialsclinical trials involving two binary endpoints

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Applications of Markov chains and discrete-time Markov processes on general state spaces (social mobility, learning theory, industrial processes, etc.) (60J20)

Cites Work

• Unnamed Item
• Using earlier measures in a longitudinal sequence as a potential surrogate for a later one
• Curtailment in single-arm two-stage phase II oncology trials
• Study Duration for Clinical Trials with Survival Response and Early Stopping Rule
• Discrete Sequential Boundaries for Clinical Trials
• Asymptotic formulas for expected sample size savings in curtailed binomial tests
• On Runs and Longest Run Tests: A Method of Finite Markov Chain Imbedding
• Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials
• A Geometric Approach to Comparing Treatments for Rapidly Fatal Diseases
• Scan statistics

This page was built for publication: Monitoring phase II comparative clinical trials with two endpoints and penalty for adverse events